Ligand Pharms General CVR earned $6.13 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $2.30 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Ligand Pharms General CVR has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Ligand Pharms General CVR earned $6.13 per diluted share in fiscal year 2025.
Ligand Pharms General CVR (LGNYZ) reported a loss of $0.22 per diluted share in fiscal year 2024 and $6.13 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Ligand Pharms General CVR (LGNYZ) reported $2.30 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Ligand Pharms General CVR (LGNYZ) diluted earnings per share went from $0.49 in fiscal year 2011 to $6.13 in fiscal year 2025.
Ligand Pharms General CVR (LGNYZ) reported -$1.43 in diluted earnings per share in Q3 2026. This represents a decrease of 125.2% from the same quarter a year earlier.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Ligand Pharms General CVR (LGNYZ) reported on that line in every period on record.
